Advancements in Neurodegenerative Treatments Drive Parkinson's Disease Therapeutics Market to US$9.2 Billion by 2031 at 7.0% CAGR | TMR Research

The global Parkinson's disease therapeutics market, valued at US$5.1 billion in 2022, is poised for robust growth. It is expected to increase at a compound annual growth rate (CAGR) of 7.0% from 2023 to 2031, reaching US$9.2 billion by 2031. This expansion reflects rising demand for treatments addressing Parkinsonism, a neurodegenerative disorder characterized as a movement disorder, basal ganglia disorder, and Lewy body disease. Driven by an aging population and therapeutic advancements, the market is set to nearly double, advancing care for this extrapyramidal disorder through 2031.

et Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26975

Understanding the Parkinson's Disease Therapeutics Market

Parkinson's disease, often termed Idiopathic Parkinsonism or Primary Parkinsonism, manifests as a tremor disorder, bradykinesia syndrome, and rigidity syndrome, with symptoms like tremors, slow movement, and muscle stiffness stemming from dopamine loss in the basal ganglia and Lewy body accumulation. Therapeutics include levodopa, dopamine agonists, and MAO-B inhibitors to manage these symptoms. The 2022 valuation of US$5.1 billion underscores the market's significance, with the projected rise to US$9.2 billion by 2031 driven by the levodopa/carbidopa segment, holding a 40% share in 2022 due to its efficacy in alleviating bradykinesia and rigidity. The 7.0% CAGR reflects treatments improving motor function by 20-30%, per clinical studies.

Key Drivers of Market Growth

Several factors are propelling the Parkinson's disease therapeutics market toward its US$9.2 billion milestone by 2031. First, the aging global population is a primary driver. By 2030, 1 in 6 people will be over 60, per WHO, increasing Parkinson's prevalence, which affects 1% of those over 60 and 3-4% over 80. With 8.5 million cases globally in 2022, per Parkinson's Foundation, demand for therapies addressing this basal ganglia disorder surges, particularly in North America, which held a 35% market share in 2022.

Second, advancements in drug development fuel growth. Novel therapies, like AbbVie's 2023 FDA-approved Duopa for advanced Parkinsonism, improve symptom management for tremor disorder and rigidity syndrome by 15%. Research into disease-modifying drugs targeting Lewy body pathology, with 139 trials in 2023, per NIH, supports the 7.0% CAGR. Companies like Teva Pharmaceutical and Novartis develop non-dopaminergic treatments, enhancing the market's trajectory to US$9.2 billion, with dopamine agonists growing at 7.5% CAGR.

Third, increased healthcare spending and awareness enhance adoption. Government funding, like the U.S.'s US$200 million for Parkinson's research in 2023, and advocacy by organizations like the Michael J. Fox Foundation drive early diagnosis and treatment of this extrapyramidal disorder. The rise in deep brain stimulation (DBS) devices, used in 10% of advanced cases, complements drug therapies, per TMR, reinforcing growth through 2031, particularly in Europe.

Leading Companies:

AbbVie, Inc.
UCB Inc.
Merck & Co., Inc.
Valeant Pharmaceuticals International, Inc.
Novartis AG
Boehringer Ingelhelm GmbH
GlaxoSmithkline Plc
Teva Pharmaceutical Industries Ltd.
STADA Arzneimittel AG

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26975 

Market Segmentation and Regional Insights

The market segments by drug class, distribution channel, and end-use. Levodopa/carbidopa led in 2022 with a 40% share, valued for managing Idiopathic Parkinsonism symptoms, while MAO-B inhibitors grow fastest at 8% CAGR for early-stage treatment. Hospital pharmacies dominated distribution at 45%, driven by inpatient care, followed by retail and online channels. End-uses include hospitals and clinics, with hospitals holding 50% share due to advanced care needs.

Regionally, North America held the largest share in 2022 at 35%, valued at US$1.79 billion, driven by the U.S.'s robust healthcare system, projecting a 7.2% CAGR. Europe follows, with a 30% share (US$1.53 billion), led by Germany and the UK, valued at US$1.7 billion in 2023. Asia-Pacific grows fastest at 7.5% CAGR, driven by China's aging population, while Latin America and Africa lag due to access barriers, per TMR.

Challenges and Opportunities

The market faces challenges. High treatment costs, averaging US$2,500 annually per patient, and side effects like dyskinesia in 30% of levodopa users pose risks. Limited disease-modifying therapies, with only 5% of drugs in Phase III trials targeting Lewy body disease, slow progress. The 7.0% CAGR reflects a market navigating these hurdles with strong demand.

These challenges present opportunities. Gene therapies, like Voyager Therapeutics' 2023 trials, could slow neurodegeneration by 10%. Emerging markets in India, growing at 8% CAGR, and digital health tools for monitoring bradykinesia syndrome offer potential. Partnerships, like Roche's 2022 collaboration with Denali Therapeutics, enhance R&D, supporting the push to US$9.2 billion.

The Road to 2031

By 2031, the global Parkinson's disease therapeutics market is projected to reach US$9.2 billion, reflecting nine years of robust growth at a 7.0% CAGR from US$5.1 billion in 2022. This milestone is driven by aging populations, therapeutic innovation, and awareness. The market's trajectory suggests continued expansion, improving quality of life for Parkinsonism patients.

In conclusion, the global Parkinson's disease therapeutics market demonstrates strong growth from 2023 to 2031. Rising from US$5.1 billion to US$9.2 billion, it addresses the needs of this neurodegenerative movement disorder with effective treatments. Stakeholders-from producers like AbbVie, Teva, and Novartis to healthcare providers-play a vital role, ensuring therapies for tremor disorder and rigidity syndrome shape a hopeful future through 2031 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Atrial Fibrillation Surgery Devices Market: https://www.pharmiweb.com/press-release/2025-03-17/atrial-fibrillation-surgery-devices-market-to-surpass-us-70-bn-by-2035-amidst-rising-demand-for-minimally-invasive-cardiac-treatments-tmr-insights

Smart Medical Implants Market: https://www.pharmiweb.com/press-release/2025-03-18/smart-medical-implants-market-to-surpass-us-248-bn-by-2035-driven-by-ai-enabled-healthcare-innovations-tmr-research

Pharma 4.0 Market: https://www.pharmiweb.com/press-release/2025-03-18/pharma-40-market-size-will-estimated-to-grow-at-a-cagr-of-177-by-2035-driven-by-digital-transformation-in-drug-manufacturing-exclusive-report-by

Dialysis Equipment Market: https://www.pharmiweb.com/press-release/2025-03-18/dialysis-equipment-market-poised-to-surpass-us-252-bn-by-2035-amidst-rising-ckd-cases-and-technological-advancements-tmr-insights

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.